Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Panel meeting prompts excitement for antiobesity drug.

Mullard A.

Lancet. 2012 Mar 10;379(9819):882. No abstract available.

PMID:
22413140
2.

The FDA's assessment of two drugs for chronic weight management.

Colman E, Golden J, Roberts M, Egan A, Weaver J, Rosebraugh C.

N Engl J Med. 2012 Oct 25;367(17):1577-9. doi: 10.1056/NEJMp1211277. Epub 2012 Oct 10. No abstract available.

3.

Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.

Bays H.

Expert Rev Cardiovasc Ther. 2010 Dec;8(12):1777-801. doi: 10.1586/erc.10.125. Epub 2010 Aug 16. Review.

PMID:
20707765
4.

2 new drugs for weight loss.

[No authors listed]

Med Lett Drugs Ther. 2012 Sep 3;54(1398):69-71. No abstract available. Erratum in: Med Lett Drugs Ther. 2012 Sep 17;54(1399):76.

PMID:
22992487
5.

Two anti-obesity hopefuls and their safety.

Bello NT, Campbell SC.

Expert Opin Drug Saf. 2012 Sep;11(5):681-3. doi: 10.1517/14740338.2012.706277. Epub 2012 Jul 13. No abstract available.

PMID:
22788876
6.

Phentermine/topiramate for weight reduction and treatment of adverse metabolic consequences in obesity.

Bays HE, Gadde KM.

Drugs Today (Barc). 2011 Dec;47(12):903-14. doi: 10.1358/dot.2011.47.12.1718738. Review. Erratum in: Drugs Today (Barc). 2012 Jan;48(1):95.

PMID:
22348915
7.

Market watch: upcoming market catalysts in Q3 2010.

Hay M.

Nat Rev Drug Discov. 2010 Jul;9(7):507. doi: 10.1038/nrd3225. No abstract available.

PMID:
20592737
8.

New antiobesity agents: lorcaserin (Belviq) and phentermine/topiramate ER (Qsymia).

Shyh G, Cheng-Lai A.

Cardiol Rev. 2014 Jan-Feb;22(1):43-50. doi: 10.1097/CRD.0000000000000001. Review.

PMID:
24304809
9.

Phentermine and topiramate extended-release for the obesity: new kids on the block.

Katsi V, Marketou M, Kallistratos MS, Tousoulis D, Makris T, Manolis AJ, Vardas P, Kallikazaros I.

Recent Pat Cardiovasc Drug Discov. 2013 Apr;8(1):35-41. Review.

PMID:
23565717
10.

Diet drugs Belviq and Qsymia receive FDA approval: what dentists need to know.

Wynn RL.

Gen Dent. 2013 Jan-Feb;61(1):11-3. No abstract available.

PMID:
23302354
11.

ACS chemical neuroscience molecule spotlight on Qnexa.

Mercer SL.

ACS Chem Neurosci. 2011 Apr 20;2(4):183-4. doi: 10.1021/cn200023v.

12.

Fixed-dose combination of phentermine-topiramate for the treatment of obesity.

Halpern B, Faria AM, Halpern A.

Expert Rev Clin Pharmacol. 2013 May;6(3):235-41. doi: 10.1586/ecp.13.13. Review.

PMID:
23656337
14.

Nonincretin drugs in later-stage development.

Zimmerman MP, Mehr SR.

Am J Manag Care. 2014 Jan;20(1 Spec No.):E2. No abstract available.

15.

Pharmacological treatment of obesity in Europe: waiting for the arrival of the white blackbird.

Rubio MA.

Endocrinol Nutr. 2014 Dec;61(10):501-4. doi: 10.1016/j.endonu.2014.11.002. English, Spanish. No abstract available.

PMID:
25434595
16.
17.

Phentermine plus topiramate in the treatment of obesity.

Malgarini RB, Pimpinella G.

Lancet. 2011 Jul 9;378(9786):125-6; author reply 126-7. doi: 10.1016/S0140-6736(11)61080-5. No abstract available.

PMID:
21742167
18.

Two new drugs approved for obesity.

Johnson AM.

S D Med. 2012 Sep;65(9):356-7. No abstract available.

PMID:
23066610
19.

Combination phentermine/topiramate for obesity treatment in primary care: a review.

Xiong GL, Gadde KM.

Postgrad Med. 2014 Mar;126(2):110-6. doi: 10.3810/pgm.2014.03.2746. Review.

PMID:
24685974
20.

Overview of new antiobesity drugs.

Hainer V.

Expert Opin Pharmacother. 2014 Oct;15(14):1975-8. doi: 10.1517/14656566.2014.946904. Epub 2014 Aug 6. Review.

PMID:
25100293

Supplemental Content

Support Center